Aytu Biopharma (AYTU) Return on Capital Employed (2011 - 2026)
Aytu Biopharma (AYTU) posted quarterly Return on Capital Employed of 26.66% for Q1 2026, down 2165.0% year-over-year from 1.29% in Q1 2025, and down 78.0% quarter-over-quarter from 14.98% in Q4 2025.
Aytu Biopharma (AYTU) Return on Capital Employed (2011 - 2026) Analysis & Trends
Aytu Biopharma (AYTU) has reported Return on Capital Employed for 16 consecutive years, with 26.66% the latest figure, recorded in Q1 2026.
- In Q1 2026, Return on Capital Employed fell 2165.0% year-over-year to 26.66%; the TTM figure through Mar 2026 stood at 26.66% (down 2165.0% YoY), while the FY2025 annual figure was 13.48%, down 1103.0% from the prior year.
- Return on Capital Employed eased to 26.66% in Q1 2026 per AYTU's latest filing, from 14.98% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 1.84% in Q1 2024 and bottomed at 123.17% in Q2 2022.
- Historically, Return on Capital Employed has averaged 38.01% across 5 years, with a median of 14.98% in 2025.
- Annual changes were most pronounced in 2022 — Return on Capital Employed plunged 7725 bps — and 2023, when it surged 9974 bps.
- Aytu Biopharma's Return on Capital Employed stood at 100.6% in 2022, then jumped by 91 bps to 9.0% in 2023, then plunged by 39 bps to 12.49% in 2024, then fell by 20 bps to 14.98% in 2025, then slumped by 78 bps to 26.66% in 2026.
- Business Quant data shows AYTU's Return on Capital Employed at 26.66% in Q1 2026, 14.98% in Q4 2025, and 14.34% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 6.60% |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 17.16% |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 6.07% |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 22.04% |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | -0.29% |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 18.67% |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 5.52% |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Aytu Biopharma | 24.49 Mn | -2.22 Mn | 7.60 Mn | -26.66% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -26.66% |
| Dec 31, 2025 | -14.98% |
| Sep 30, 2025 | -14.34% |
| Jun 30, 2025 | -12.80% |
| Mar 31, 2025 | -5.00% |
| Dec 31, 2024 | -12.49% |
| Sep 30, 2024 | -2.97% |
| Jun 30, 2024 | -2.60% |
| Mar 31, 2024 | 1.84% |
| Dec 31, 2023 | -9.00% |
| Sep 30, 2023 | -23.30% |
| Jun 30, 2023 | -23.43% |
| Mar 31, 2023 | -58.01% |
| Dec 31, 2022 | -100.60% |
| Sep 30, 2022 | -118.21% |
| Jun 30, 2022 | -123.17% |
| Mar 31, 2022 | -100.45% |
| Dec 31, 2021 | -54.82% |
| Sep 30, 2021 | -40.96% |
| Jun 30, 2021 | -169.74% |